Company research
Edgewise Therapeutics, Inc.
CIK 1710072Updated Sep 24, 2026
SecurityEWTX · NASDAQ · equity
EWTX price & chart
Loading TradingView…
NASDAQ:EWTX on TradingView ↗About the company
Edgewise Therapeutics is a leading biopharmaceutical company focused on novel, muscle-targeted therapeutics. Leveraging its expertise in muscle biology and small molecule drug development, Edgewise is advancing a cardiovascular pipeline targeting significant unmet needs, including hypertrophic cardiomyopathy, heart failure and other serious cardiovascular and cardiometabolic conditions. To learn more, go to edgewisetx.com or follow Edgewise on LinkedIn, X, Facebook and Instagram.
In the news
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules News provided by Edgewise Therapeutics Jan 05, 2026, 08:00 ET Share this article Share to X Share this article Share to X BOULDER, Colo. , Jan. 5, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or ↗
Seeking Alpha
Edgewise Therapeutics, Inc. (EWTX) Discusses Differentiated Mechanism of Action of Cardiac Sarcomere Modulator EDG-7500 Transcript ↗
Edgewise Therapeutics, Inc. (EWTX) Discusses Differentiated Mechanism of Action of Cardiac Sarcomere Modulator EDG-7500 - Slideshow ↗
Tracking Baker Brothers' Portfolio: Q2 2026 Update ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 552,603,000Source | 486,817,000Source | 340,035,000Source | 367,101,000Source |
| Property, Plant and Equipment, NetUSD | 7,831,000Source | 9,503,000Source | 10,443,000Source | 8,533,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 61,148,000Source | 41,666,000Source | 86,097,000Source | 21,993,000Source |
| Assets, CurrentUSD | 543,385,000Source | 475,483,000Source | 326,997,000Source | 356,999,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 13,276,000Source | 5,313,000Source | 8,604,000Source | 5,052,000Source |
| Operating Lease, Right-of-Use AssetUSD | 1,387,000Source | 1,569,000Source | 2,247,000Source | 1,318,000Source |
| Other Assets, NoncurrentUSD | — | 262,000Source | 348,000Source | 251,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 30,346,000Source | 27,601,000Source | 21,205,000Source | 20,385,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 10,000Source | 9,000Source | 7,000Source | 6,000Source |
| Additional Paid in CapitalUSD | 1,067,941,000Source | 837,363,000Source | 563,487,000Source | 492,665,000Source |
| Retained Earnings (Accumulated Deficit)USD | -546,371,000Source | -378,576,000Source | -244,763,000Source | -144,600,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 677,000Source | 420,000Source | 99,000Source | -1,355,000Source |
| Stockholders' Equity Attributable to ParentUSD | 522,257,000Source | 459,216,000Source | 318,830,000Source | 346,716,000Source |
| Liabilities and EquityUSD | 552,603,000Source | 486,817,000Source | 340,035,000Source | 367,101,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 27,370,000Source | 23,860,000Source | 16,771,000Source | 16,585,000Source |
| Operating Lease, Liability, CurrentUSD | 1,014,000Source | 996,000Source | 980,000Source | 608,000Source |
| Accounts Payable, CurrentUSD | 6,006,000Source | 5,579,000Source | 4,025,000Source | 6,105,000Source |
| Operating Lease, Liability, NoncurrentUSD | 2,976,000Source | 3,741,000Source | 4,434,000Source | 3,800,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 7,920,000Source | 7,229,000Source | 6,071,000Source | 5,840,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -167,795,000Source | -133,813,000Source | -100,163,000Source | -67,640,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 34,752,000Source | 24,712,000Source | 17,560,000Source | 10,924,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | 272,000Source | 1,737,000Source | -92,000Source | 47,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -143,816,000Source | -109,028,000Source | -91,948,000Source | -52,635,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -32,790,000Source | -184,656,000Source | 102,886,000Source | -70,577,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 256,000Source | 1,312,000Source | 5,745,000Source | 5,546,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 196,088,000Source | 249,253,000Source | 53,166,000Source | 129,639,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 19,482,000Source | -44,431,000Source | 64,104,000Source | 6,427,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 61,148,000Source | 41,666,000Source | 86,097,000Source | 21,993,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 34,752,000Source | 24,711,000Source | 17,560,000Source | 10,924,000Source |
| DepreciationUSD | 2,084,000Source | 2,069,000Source | 1,551,000Source | 368,000Source |
| General and Administrative ExpenseUSD | 40,017,000Source | 31,866,000Source | 23,452,000Source | 17,626,000Source |
| Income Tax Expense (Benefit)USD | 4,000Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -167,795,000Source | -133,813,000Source | -100,163,000Source | -67,640,000Source |
| Operating ExpensesUSD | 191,406,000Source | 158,832,000Source | 114,357,000Source | 71,658,000Source |
| Proceeds from Issuance of Common StockUSD | 187,362,000Source | 239,147,000Source | 52,618,000Source | 129,165,000Source |
| Proceeds from Stock Options ExercisedUSD | 7,803,000Source | 9,480,000Source | 117,000Source | 405,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -191,406,000Source | -158,832,000Source | -114,357,000Source | -71,658,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -167,800,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | 4,000Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -167,795,000Source | -133,813,000Source | -100,163,000Source | -67,640,000Source |
| Earnings Per Share, BasicUSD per share | -1.63Source | -1.45Source | -1.57Source | -1.26Source |
| Earnings Per Share, DilutedUSD per share | -1.63Source | -1.45Source | -1.57Source | -1.26Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 102,930,744Source | 92,414,626Source | 63,723,600Source | 53,593,753Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 102,930,744Source | 92,414,626Source | 63,723,600Source | 53,593,753Source |
| Additional Financial Items | ||||
| General and Administrative ExpenseUSD | 40,017,000Source | 31,866,000Source | 23,452,000Source | 17,626,000Source |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | — | -1.45Source | -1.57Source | -1.26Source |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | — | -1.45Source | -1.57Source | -1.26Source |
| Interest Income, OtherUSD | 23,611,000Source | 25,019,000Source | 14,194,000Source | 4,018,000Source |
| Operating ExpensesUSD | 191,406,000Source | 158,832,000Source | 114,357,000Source | 71,658,000Source |
| Research and Development ExpenseUSD | 151,389,000Source | 126,966,000Source | 90,905,000Source | 54,032,000Source |
Filing attachments
tm2621653d1_ex99-1.htm · 8-K · 2026-08-06
EX-99.1 2 tm2621653d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 News Release Edgewise Therapeutics Reports Second Quarter 2026 Financial Results - Announced positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) - - Completed sale of sevasemten and muscular dystrophy business to Servier for up to $2.65 billion in July 2026, strengthening the balance sheet, sharpening focus on the cardiovascular pipeline …
Read attachment ↗tm2620181d2_ex99-1.htm · 8-K/A · 2026-07-16
EX-99.1 2 tm2620181d2_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 EDGEWISE THERAPEUTICS, INC. UNAUDITED PRO FORMA CONDENSED FINANCIAL INFORMATION On May 31, 2026, Edgewise Therapeutics, Inc. (“Edgewise” or the “Company”) entered into a definitive Asset Purchase Agreement (the “APA”) with Servier Pharmaceuticals LLC and Les Laboratoires Servier (together, “Servier” or the “Buyers”), pursuant to which Servier acquired the Company's sevasemten muscular dystrophy program, including the related intel…
Read attachment ↗tm2620181d1_ex99-1.htm · 8-K · 2026-07-13
EX-99.1 2 tm2620181d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 NEWS RELEASE Edgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline - Edgewise receives $1.55 billion in upfront cash and is eligible to receive up to $1.1 billion in regulatory and commercial milestones - - Transaction creates strategically focused cardiovascular company - - Upfront proceeds expected to fully fund EDG-7500 de…
Read attachment ↗d24037dex991.htm · 8-K · 2026-06-01
EX-99.1 2 d24037dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 NEWS RELEASE ──────────────── Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline - Edgewise to Receive $1.55 Billion in Upfront Cash Consideration and is Eligible to Receive up to $1.1 Billion in Regulatory and Commercial Milestones - - Transaction Creates Focused Cardiovascular Company with Enhanced Strategic Clarity - -…
Read attachment ↗tm2613489d1_ex99-1.htm · 8-K · 2026-05-07
EX-99.1 2 tm2613489d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 News Release Edgewise Therapeutics Reports First Quarter 2026 Financial Results and Advances Clinical Programs in Muscular Dystrophy and Cardiovascular Indications - Announced positive long-term sevasemten data demonstrating sustained functional stabilization in Becker muscular dystrophy (Becker) up to 3.5 years of follow-up - - CIRRUS-HCM 12-week data of EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (H…
Read attachment ↗tm266859d1_ex99-1.htm · 8-K · 2026-02-26
EX-99.1 2 tm266859d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 News Release ──────────────── Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs - CIRRUS-HCM 12-week data of EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) expected in H1 2026 - - Phase 1 healthy adult trial data of EDG-15400 and plans for heart failure studies expected in H1 2026 - - Pivotal…
Read attachment ↗